| Log in
Photo Credit: Reuters

Pfizer adds $600 mn to VC arm; 25% to flow into early-stage neuroscience research

07 June, 2018

Pfizer Inc said on Wednesday it planned to invest $600 million in its venture capital fund, a quarter of which would be earmarked for promising research on neuroscience.

The new funding will bring total assets managed by Pfizer Ventures to over $1 billion, the company said in a statement.

The announcement comes six months after the U.S. drugmaker said it was abandoning research to find new drugs aimed at treating Alzheimer’s and Parkinson’s diseases.

Several drugmakers, including Pfizer, have cut back on neuroscience research after a string of costly trials yielded disappointing results, with some of them betting on startups that are focusing on such areas.

Pfizer has already invested in six neuroscience companies and, alongside drugmakers such as GlaxoSmithKline (GSK.L) and Eli Lilly (LLY.N), is part of the Dementia Discovery Fund, which has raised more than $190 million since its 2015 launch.

Pfizer Ventures will seek to invest $150 million in early-stage neuroscience companies, particularly those focusing on neuro-degeneration, neuro-inflammation and neuro-metabolic disorders.

Like this report? Sign up for our daily newsletter to get our top reports.


Leave Your Comment
Exclusive: Century Pharma hires banker for fresh fundraise; existing investor to exit

Exclusive: Century Pharma hires banker for fresh fundraise; existing investor to exit

Joseph Rai 1 year ago
Drugmaker Century Pharmaceuticals Ltd has hired an investment bank as it seeks...
Mayfield raising second India-focused VC fund

Mayfield raising second India-focused VC fund

Bhawna Gupta 5 years ago
Silicon Valley-based venture capital firm Mayfield Fund is in the process of...
IDG Ventures India marks final close of third fund

IDG Ventures India marks final close of third fund

Joseph Rai 1 year ago
Venture capital firm IDG Ventures India has marked the final close of its third...
No Comments

Pfizer adds $600 mn to VC arm; 25% to flow into early-stage neuroscience research

Powered by WordPress.com VIP